The FDA has recognized the combination of DNMT inhibitors and venetoclax as a “breakthrough therapy” for AML patients who cannot undergo intensive chemotherapy, and it is undergoing clinical trials for MDS and AML [251,252]. Here, DNMT1 is linked to acute myeloid leukemia.